Effects of rimonabant on the reinstatement of nicotine-conditioned place preference by drug priming in rats

Behavioural Brain Research

Volumn 202, Issue 2, 2009, Pages 260-265

  Biala, Grazyna ^a   Budzynska, Barbara ^a   Staniak, Natasza ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

CB1 cannabinoid receptors; Morphine; Nicotine; Place conditioning; Rats; Reinstatement; Rimonabant

Indexed keywords

CANNABINOID 1 RECEPTOR ANTAGONIST; MORPHINE; NICOTINE; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; CONDITIONING; CONTROLLED STUDY; DOSE RESPONSE; DRUG DEPENDENCE TREATMENT; DRUG EFFECT; LOCOMOTION; MALE; MORPHINE ADDICTION; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; PROVOCATION TEST; RAT; RELAPSE; TOBACCO DEPENDENCE;

ANALYSIS OF VARIANCE; ANIMALS; CENTRAL NERVOUS SYSTEM AGENTS; CONDITIONING, CLASSICAL; EXTINCTION, PSYCHOLOGICAL; MALE; MORPHINE; NICOTINE; NICOTINIC AGONISTS; PIPERIDINES; PYRAZOLES; RANDOM ALLOCATION; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; SPATIAL BEHAVIOR;

EID: 67349282720     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.03.042     Document Type: Article

References (57)

1. Bell S.M., Stewart R.B., Thompson S.C., and Meisch R.A. Food-deprivation increases cocaine-induced conditioned place preference and locomotor activity in rats. Psychopharmacology 131 (1997) 8211-8218
2. Berrendero F., Kieffer B.L., and Maldonado R. Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in μ-opioid receptor knock-out mice. J Neurosci 22 (2002) 10935-10940
3. Berrendero F., Mendizabal V., Robledo P., Galeote L., Bilkei-Gorzo A., Zimmer A., et al. Nicotine-induced antinociception, rewarding effects, and physical dependence are decreased in mice lacking the preproenkephalin gene. J Neurosci 25 (2005) 1103-1112
4. Biala G. Calcium channel antagonists suppress nicotine-induced place preference and locomotor sensitization in rodents. Pol J Pharmacol 55 (2003) 327-335
5. Biala G., and Budzynska B. Calcium-dependent mechanisms of the reinstatement of nicotine-conditioned place preference by drug priming in rats. Pharmacol Biochem Behav 89 (2008) 116-125
6. Biala G., and Budzynska B. Reinstatement of nicotine-conditioned place preference by drug priming: effects of calcium channel antagonists. Eur J Pharmacol 537 (2006) 85-93
7. Biala G., Budzynska B., and Kruk M. Naloxone precipitates nicotine abstinence syndrome and attenuates nicotine-induced antinociception in mice. Pharmacol Rep 57 (2005) 755-760
8. Biala G., and Weglińska B. On the mechanism of cross-tolerance between morphine- and nicotine-induced antinociception: involvement of calcium channels. Prog Neuropsychopharmacol Biol Psychiatry 30 (2006) 15-21
9. Bozarth M. The mesolimbic dopamine system as a model of reward system. In: Willner P., and Scheel-Krüger J. (Eds). The mesolimbic dopamine system: from motivation to action (1991), Wiley, Chichester 301-330
10. Caggiula A.R., Donny E.C., Chaudhri N., Perkins K.A., Evans-Martin F.F., and Sved A.F. Importance of nonpharmacological factors in nicotine self-administration. Physiol Behav 77 (2002) 683-687
11. Calcagnetti D.J., and Schechter M.D. Nicotine place preference using the biased method of conditioning. Prog NeuroPsychopharmacol Biol Psychiatry 18 (1994) 925-933
12. Carr K.D. Augmentation of drug reward by chronic food restriction: behavioral evidence and underlying mechanisms. Physiol Behav 76 (2002) 353-364
13. Castane A., Valjent E., Ledent C., Parmentier M., Maldonado R., and Valverde O. Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology 43 (2002) 857-867
14. Chaperon F., Soubrié P., Puech A.J., and Thiébot M.H. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology 135 (1998) 324-332
15. Chaudhri N., Caggiula A.R., Donny E.C., Booth S., Gharib M., Craven L., et al. Operant responding for conditioned and unconditioned reinforcers in rats is differentially enhanced by the primary reinforcing and reinforcement-enhancing effects of nicotine. Psychopharmacology 189 (2006) 27-36
16. Cohen C., Perrault G., Griebel G., and Soubrié P. Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonists, rimonabant. Neuropsychopharmacology 30 (2005) 145-155
17. Cohen C., Perrault G., Voltz C., Steinberg R., and Soubrié P. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 13 (2002) 451-463
18. Davenport K.E., Houdi A.A., and Van Loon G.R. Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain. Neurosci Lett 113 (1990) 40-46
19. De Vries T.J., Homberg J.R., Binnekade R., Raasø H., and Schoffelmeer A.N. Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology 168 (2003) 164-169
20. De Vries T.J., Shaham Y., Homberg J.R., Crombag H., Schuurman K., Dieben J., et al. A cannabinoid mechanism in relapse to cocaine seeking. Nat Med (2001) 1151-1154
21. Fattore L., Spano S., Cossu G., Deiana S., Fadda P., and Fratta W. Cannabinoid CB(1) antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats. Neuropharmacology 48 (2005) 1097-1104
22. Fiserova M., Consolo S., and Krsiak M. Chronic morphine induces long-lasting changes in acetylcholine release in rat nucleus accumbens core and shell: an in vivo microdialysis study. Psychopharmacology 142 (1999) 85-94
23. Forget B., Barthélémy S., Saurini F., Hamon M., and Thiébot M.H. Differential involvement of the endocannabinoid system in short- and long-term expression of incentive learning supported by nicotine in rats. Psychopharmacology 189 (2006) 59-69
24. Ghozland S., Matthes H.W., Simonin F., Filliol D., Kieffer B.L., and Maldonado R. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. Neuroscience 22 (2002) 1146-1154
25. Houdi A.A., Dasgupta R., and Kindy M.S. Effect of nicotine use and withdrawal on brain preproenkephalin A mRNA. Brain Res 799 (1998) 257-263
26. Isola R., Zhang H., Duchemin A.M., Tejwani G.A., Neff N.H., and Hadjiconstantinou M. Met-enkephalin and preproenkephalin mRNA changes in the striatum of the nicotine abstinence mouse. Neurosci Lett 325 (2002) 67-71
27. Itzhak Y., and Martin J.L. Cocaine-induced conditioned place preference in mice: induction, extinction and reinstatement by related psychostimulants. Neuropsychopharmacology 26 (2002) 130-134
28. Justinova Z., Tanda G., Munzar P., and Goldberg S.R. The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. Psychopharmacology 173 (2004) 186-194
29. Kelsey J.E., and Calabro S. Rimonabant blocks the expression but not the development of locomotor sensitization to nicotine in rats. Psychopharmacology 198 (2008) 461-466
30. Kenford S.L., Fiore M.C., Jorenby D.E., Smith S.S., Wetter D., and Baker T.B. Predicting smoking cessation. Who will quit with and without the nicotine patch. JAMA 271 (1994) 589-594
31. Koob G.F., and Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24 (2001) 97-129
32. Le Foll B., and Goldberg S.R. Rimonabant, a CB1 antagonist, block nicotine-conditioned place preference. Neuroreport 15 (2004) 2139-2143
33. Ledent C., Valverde O., Cossu G., Petitet F., Aubert J.F., Beslot F., et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283 (1999) 401-404
34. Li F., Fang Q., Liu Y., Zhao M., Li D., Wang J., et al. Cannabinoid CB(1) receptor antagonist rimonabant attenuates reinstatement of ketamine conditioned place preference in rats. Eur J Pharmacol 28 589 (2008) 122-126
35. Mailleux P., and Vanderhaeghen J. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 48 (1992) 655-668
36. Maldonado R. Study of cannabinoid dependence in animals. Pharmacol Ther 95 (2002) 153-164
37. Manzanares J., Corchero J., Romero J., Fernández-Ruiz J.J., Ramos J.A., and Fuentes J.A. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 20 (1999) 287-294
38. Martin M., Ledent C., Parmentier M., Maldonado R., and Valverde O. Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur J Neurosci 12 (2000) 4038-4046
39. McClernon F.J., Kozink R.V., and Rose J.E. Individual differences in nicotine dependence, withdrawal symptoms, and sex predict transient fMRI-BOLD responses to smoking cues. Neuropsychopharmacology 33 (2008) 2148-2157
40. Mueller D., Perdikaris D., and Stewart J. Persistence and drug-induced reinstatement of a morphine-induced conditioned place preference. Behav Brain Res 136 (2002) 389-397
41. Mueller D., and Stewart J. Cocaine-induced conditioned place preference: reinstatement by priming injections of cocaine after extinction. Behav Brain Res 115 (2000) 39-47
42. Navarro M., Carrera M.R., Fratta W., Valverde O., Cossu G., Fattore L., et al. Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 21 (2001) 5344-5350
43. Navarro M., Chowen J., Rocío A., Carrera M., del Arco I., Villanúa M.A., et al. CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats. Neuroreport 9 (1998) 3397-3402
44. Nestler E.J. Molecular mechanisms of drug addiction. Neuropharmacology 47 (2004) 24-32
45. Parker L.A., and Mcdonald R.V. Reinstatement of both a conditioned place preference and a conditioned place aversion with drug primes. Pharmacol Biochem Behav 66 (2000) 559-561
46. Pickel V.M., Chan J., Kash T.L., Rodríguez J.J., and MacKie K. Compartment-specific localization of cannabinoid 1 (CB1) and mu-opioid receptors in rat nucleus accumbens. Neuroscience 127 (2004) 101-112
47. Pierce R.C., and Kalivas P.W. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Brain Res Rev 25 (1997) 192-216
48. Pomerleau O.F. Endogenous opioids and smoking: a review of progress and problems. Psychoneuroendocrinology 23 (1998) 115-130
49. Rezayof A., Zatali H., Haeri-Rohani A., and Zarrindast M.R. Dorsal hippocampal muscarinic and nicotinic receptors are involved in mediating morphine reward. Behav Brain Res 166 (2006) 281-290
50. Rinaldi-Carmona M., Barth F., Héaulme M., Shire D., Calandra B., Congy C., et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350 (1994) 240-244
51. Singh M.E., Verty A.N., McGregor I.S., and Mallet P.E. A cannabinoid receptor antagonist attenuates conditioned place preference but not behavioural sensitization to morphine. Brain Res 1026 (2004) 244-253
52. Taguchi K., Hagiwara Y., Suzuki Y., and Kubo T. Effects of morphine on release of acetylcholine in the rat striatum: an in vivo microdialysis study. Naunyn Schmiedebergs Arch Pharmacol 347 (1993) 9-13
53. Tzschentke T.M. Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol 12 (2007) 227-462
54. Valjent E., Mitchell J.M., Besson M.J., Caboche J., and Maldonado R. Behavioural and biochemical evidence for interactions between delta 9-tetrahydrocannabinol and nicotine. Br J Pharmacol 135 (2002) 564-578
55. Valverde O., Robledo P., and Maldonado R. Involvement of the endogenous opioid system in cannabinoid responses. Cur Med Chem 4 (2004) 183-193
56. Wewers M.E., Dhatt R.K., Snively T.A., and Tejwani G.A. The effect of chronic administration of nicotine on antinociception, opioid receptor binding and met-enkephalin levels in rats. Brain Res 822 (1999) 107-113
57. Zarrindast M.R., Khoshayand M.R., and Shafaghi B. The development of cross-tolerance between morphine and nicotine in mice. Eur Neuropsychopharmacol 9 (1999) 227-233